Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 1/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 19/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enviroxime SCHEMBL3585 | 1.00 | PI4KB (1.00) | PI4KBMAPK14CYP3A4 | |
| Viroxime SCHEMBL29365398 | 1.00 | PI4KB (1.00) | PI4KBMAPK14CYP3A4 | |
| Viroxime SCHEMBL3586 | 1.00 | PI4KB (1.00) | PI4KBMAPK14CYP3A4 | |
| Enviroxime SCHEMBL6475190 | 0.86 | PI4KB (0.74) | PI4KBMAPK14CYP3A4 | |
| SCHEMBL10906292 | 0.85 | PI4KB (0.74) | PI4KBMAPK14CYP3A4 | |
| SCHEMBL4837467 | 0.85 | PI4KB (0.74) | PI4KBMAPK14CYP3A4 | |
| SCHEMBL11073939 | 0.84 | PI4KB (0.72) | PI4KBMAPK14CYP3A4 | |
| SCHEMBL11149101 | 0.83 | PI4KB (0.71) | PI4KBMAPK14CYP3A4 | |
| Enviradene SCHEMBL10429409 | 0.83 | PI4KB (0.71) | PI4KBMAPK14CYP3A4 | |
| Enviradene SCHEMBL29367493 | 0.83 | PI4KB (0.71) | PI4KBMAPK14CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4262812-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | Southern Research Institute (US) | 2023-10-25 | — | — | EP | claimed |
| WO-2023122212-A2 | SUBSTITUTED PHENYL ETHYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | claimed |
| CN-115916175-A | Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses | 南方研究院 | 2023-04-04 | — | — | CN | claimed |
| EP-4125845-A1 | NOVEL 2-PYRIMIDONE ANALOGS AS POTENT ANTIVIRAL AGENTS AGAINST ALPHAVIRUSES | Southern Research Institute (US) | 2023-02-08 | — | — | EP | claimed |
| EP-4021413-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2022133323-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2021203048-A1 | NOVEL 2-PYRIMIDONE ANALOGS AS POTENT ANTIVIRAL AGENTS AGAINST ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2021-10-07 | — | — | WO | claimed |
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | Spectral Analytics, Inc. (US) | 2021-09-30 | — | — | US | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| EP-1434602-A2 | CPG FORMULATIONS AND RELATED METHODS | Merial Limited (US) | 2004-07-07 | — | — | EP | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| US-6576636-B2 | Treating a noncentral nervous system by administering a covalent conjugate of a C8-26, unbranched, naturally occurring fatty acid and a drug, provided the drug is not an adenosine receptor agonist/antagonist; anticarcinogenics | PROTARGA, INC. | 2003-06-10 | — | — | US | claimed |
| WO-2003030934-A2 | CPG FORMULATIONS AND RELATED METHODS | MERIAL LIMITED (US) | 2003-04-17 | — | — | WO | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |
| WO-2001097749-A2 | THE USE OF SYNTHETIC, NON-HORMONAL 21-AMINOSTEROIDS AND THEREOF | KOTZE, GAVIN, SALOMON (ZA) | 2001-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | NCOA1, NCOA2, NCOA3 | PI4KB 3767/4885MAPK14 2822/4885CYP3A4 398/4885 |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | VHL, IDH2, AIFM2 | PI4KB 889/4885MAPK14 4118/4885CYP3A4 2621/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | PI4KB 1409/4885MAPK14 3074/4885CYP3A4 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.